Search form
Search
contact us
Navigation
home
boards
job ratings
cp wire
medtech news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» SEC
SEC
SEC says Eli Lilly can't avoid requests for more info on diversity efforts, abortion stance
SEC says Eli Lilly can't avoid requests for more info on diversity efforts, abortion stance
Endpoints
Eli Lilly
SEC
abortion
diversity
DEI
Indiana
Flag link:
Viatris executive charged in insider trading scheme that allegedly netted $7.2 million
Viatris executive charged in insider trading scheme that allegedly netted $7.2 million
Fierce Pharma
Viatris
insider trading
SEC
Flag link:
Zymergen Cuts 80 More Jobs, Parts Ways with Co-Founder
Zymergen Cuts 80 More Jobs, Parts Ways with Co-Founder
BioSpace
Zymergen
SEC
layoffs
Flag link:
AbbVie calls off PhI trial for I-Mab’s CD47 days after Zai Lab shelves its own program
AbbVie calls off PhI trial for I-Mab’s CD47 days after Zai Lab shelves its own program
Endpoints
AbbVie
CD47
SEC
clinical trials
I-Mab
Zai Lab
Flag link:
For accounting purposes, Biogen says its $223M inventory of Aduhelm is basically worthless
For accounting purposes, Biogen says its $223M inventory of Aduhelm is basically worthless
Endpoints
Biogen
Aduhelm
Alzheimer's disease
SEC
Flag link:
Epizyme SEC filing details its desperate days in free fall before $247M sale to Ipsen
Epizyme SEC filing details its desperate days in free fall before $247M sale to Ipsen
Fierce Pharma
Epizyme
SEC
M&A
Ipsen
Flag link:
How Pfizer CEO Bourla's evening call brought Biohaven back into the M&A fold
How Pfizer CEO Bourla's evening call brought Biohaven back into the M&A fold
Fierce Pharma
Pfizer
Pfizer CEOs
Albert Bourla
M&A
Biohaven
SEC
Flag link:
Former AstraZeneca exec committed insider trading on landmark 2019 Enhertu deal, SEC alleges
Former AstraZeneca exec committed insider trading on landmark 2019 Enhertu deal, SEC alleges
Endpoints
AstraZeneca
insider trading
SEC
Enhertu
Daiichi Sankyo
Flag link:
In wake of Biogen's skirmish with the SEC, pharma giants are changing the way they do quarterly reports
In wake of Biogen's skirmish with the SEC, pharma giants are changing the way they do quarterly reports
Endpoints
Biogen
earnings
SEC
Eli Lilly
Merck
Bristol Myers Squibb
Pfizer
AbbVie
Flag link:
SEC to propose new rules to rein in SPACs
SEC to propose new rules to rein in SPACs
Endpoints
SEC
regulatory
SPACs
Flag link:
Baxter hit with $18M SEC penalty for accounting improprieties
Baxter hit with $18M SEC penalty for accounting improprieties
Medtech Dive
devices
Medtech
SEC
Baxter International
Flag link:
Biogen says U.S. FTC, SEC probing Alzheimer's disease drug
Biogen says U.S. FTC, SEC probing Alzheimer's disease drug
Reuters
Biogen
Aduhelm
FTC
SEC
Alzheimer's disease
Flag link:
Novartis, Amgen settle their dueling lawsuits over migraine drug Aimovig
Novartis, Amgen settle their dueling lawsuits over migraine drug Aimovig
Fierce Pharma
Amgen
Novartis
Aimovig
migraines
SEC
Flag link:
Fore fires CEO Malik after SEC insider trading charges during his time as Immunomedics CFO
Fore fires CEO Malik after SEC insider trading charges during his time as Immunomedics CFO
Fierce Biotech
SEC
insider trading
Immunomedics
Usama Malik
Flag link:
Cassava Sciences under SEC probe for manipulating Alzheimer’s drug data
Cassava Sciences under SEC probe for manipulating Alzheimer’s drug data
Seeking Alpha
Cassava Sciences
SEC
data manipulation
Alzheimer's disease
Flag link:
The SEC Wants Badly Behaved Companies to Admit They Did Wrong
The SEC Wants Badly Behaved Companies to Admit They Did Wrong
Motley Fool
SEC
regulatory
Flag link:
5 years after Pfizer buyout, SEC charges Medivation's ex-dealmaking lead with insider trading
5 years after Pfizer buyout, SEC charges Medivation's ex-dealmaking lead with insider trading
Fierce Pharma
Medivation
Pfizer
M&A
SEC
insider trading
Flag link:
CytoDyn catches SEC, DOJ scrutiny over public claims about COVID-19 drug's viability
CytoDyn catches SEC, DOJ scrutiny over public claims about COVID-19 drug's viability
Fierce Biotech
CytoDyn
FDA
COVID-19
DOJ
SEC
Flag link:
SPAC listings slow as the hunt for deals continues
SPAC listings slow as the hunt for deals continues
EP Vantage
SPACs
SEC
Flag link:
Health tech SPAC deals on pause
Health tech SPAC deals on pause
EP Vantage
SPAC
M&A
SEC
Flag link:
Pages
1
2
3
4
5
6
7
8
next ›
last »